Danaher Corp (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Ticker
DHR
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$161.72B
52-week range
$160.93 - $242.80

Valuation

Share price
$230.11 (close of Nov 16, 2026)
P/E (TTM)
37.57x
Price to book
3.02x
Price to free cash flow
28.24x
Enterprise value
$182.52B
Book value per share
$76.25

Price performance

PeriodChange
1 day-1.25%
5 days-2.13%
1 month+0.47%
3 months+13.66%
6 months+42.12%
Year to date+0.52%
1 year+4.02%
3 years+17.42%
5 years-14.73%
10 years+220.66%
All time+302,127.54%

Short interest

As of
Oct 30, 2026
Short % of float
1.34%
Shares short
8.38M
Days to cover
1.76
Change since prior report
+2.94%
Source
FINRA consolidated short interest

Members of Congress who disclosed DHR trades

Julie Johnson · Jefferson Shreve · Robert Bresnahan · Kevin Hern · Lisa McClain · Thomas Kean · Alan Armstrong · Bruce Westerman · Dan Newhouse · Gilbert Ray Cisneros · Greg Landsman · Julia Letlow

And 4 others

Super investors holding DHR

Ken Griffin (Citadel) · Pat Dorsey (Dorsey Asset Management) · First Pacific Advisors (First Pacific Advisors, LP) · Dan Loeb (Third Point LLC) · Wallace Weitz (Weitz Investment Management) · Chase Coleman (Tiger Global Management) · Bill Gates (Gates Foundation Trust) · Dodge & Cox (Dodge & Cox Funds) · Stanley Druckenmiller (Duquesne Family Office) · Ray Dalio (Bridgewater Associates) · David Katz (Matrix Asset Advisors Inc) · Bill Nygren (Harris Associates LP)

And 1 other

Profitability and growth

Return on equity
6.88%
Return on invested capital
5.62%
Return on assets
4.33%
Return on capital employed
6.12%
Gross margin
59.11%
Net margin
14.71%
EBITDA margin
29.05%
Revenue growth
2.90%
Net income growth
-7.31%
Free cash flow growth
-0.68%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.54%
Current ratio
1.63x
Net debt to EBITDA
2.66x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$24.57B
Cost of revenue
$10.04B
Gross profit
$14.52B
EBITDA
$7.14B
Net income
$3.61B
Earnings per share
$5.07
Research and development
$1.60B
Interest expense
$265.00M
Shares outstanding
712.70M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$24.57B$14.52B$3.61B$5.07
2024-12-31$23.88B$14.21B$3.90B$5.33
2023-12-31$23.89B$14.03B$4.76B$6.44
2022-12-31$26.64B$16.19B$7.21B$9.80
2021-12-31$24.80B$15.24B$6.43B$8.77
2020-12-31$22.28B$12.47B$3.65B$4.97
2019-12-31$17.91B$9.98B$3.01B$4.11
2018-12-31$17.05B$9.51B$2.65B$3.78
2017-12-31$15.52B$8.57B$2.49B$3.58
2016-12-31$16.88B$9.33B$2.55B$3.69

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3159.11%14.71%6.88%5.62%
2024-12-3159.50%16.33%7.87%6.17%
2023-12-3158.74%19.94%8.91%6.00%
2022-12-3160.76%27.06%14.39%9.50%
2021-12-3161.44%25.94%14.24%7.76%
2020-12-3155.98%16.36%9.17%5.46%
2019-12-3155.74%16.79%9.93%4.54%
2018-12-3155.75%15.55%9.39%6.58%
2017-12-3155.23%16.06%9.45%5.97%
2016-12-3155.29%15.13%11.07%6.44%

Cash and debt by year

Period endCashDebt
2025-12-31$4.62B$18.42B
2024-12-31$2.08B$15.50B
2023-12-31$5.86B$16.71B
2022-12-31$6.00B$19.09B
2021-12-31$2.59B$22.17B
2020-12-31$6.04B$21.19B
2019-12-31$19.91B$21.52B
2018-12-31$787.80M$9.69B
2017-12-31$630.30M$10.33B
2016-12-31$963.70M$9.67B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$5.26B$298.00M
2024-12-31$5.30B$288.00M
2023-12-31$5.78B$306.00M
2022-12-31$7.40B$295.00M
2021-12-31$7.12B$184.00M
2020-12-31$5.42B$187.00M
2019-12-31$3.32B$159.00M
2018-12-31$3.44B$138.00M
2017-12-31$2.91B$127.10M
2016-12-31$2.93B$129.80M

Dividend history

Most recent payment
Sep 30, 2026
Paid in the last twelve months
$1.52
Payment dateDividend per share
2026-09-30$0.40
2026-06-26$0.40
2026-03-27$0.40
2025-12-26$0.32
2025-09-26$0.32
2025-06-27$0.32
2025-03-28$0.32
2024-12-27$0.27

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-21Sep 2026$1.92
2026-07-21Jun 2026$1.84
2026-04-21Mar 2026$1.94
2026-01-28Dec 2025$2.22
2025-10-21Sep 2025$1.71
2025-07-22Jun 2025$1.64
2025-04-22Mar 2025$1.62
2025-01-29Dec 2024$2.17

Filings and sources

Company website
danaher.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Natera, Inc. (NTRA) · Thermo Fisher Scientific Inc. (TMO) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV) · IDEXX Laboratories Inc (IDXX) · Waters Corp (WAT) · Illumina, Inc. (ILMN) · Mettler-Toledo International Inc (MTD)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades